Form 4: Keros Therapeutics Director Julius Knowles Reports New Equity Compensation and Beneficial Ownership

Keros Therapeutics, Inc. Director Julius Knowles has reported the acquisition of restricted stock units and stock options, aligning his interests with shareholders.

Summary

• Julius Knowles, a Director of Keros Therapeutics, Inc. (KROS), acquired 5,250 restricted stock units (RSUs) at a price of $0.
• He also acquired stock options to purchase 10,500 shares of Common Stock at an exercise price of $14.82 per share.
• The RSUs will fully vest on the earlier of June 4, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• The stock options will vest in equal quarterly installments over 12 months following the grant date, fully vested by the 2026 annual meeting, subject to continued service.
• Following these transactions, Mr. Knowles directly beneficially owns 6,441 shares of Common Stock and 10,500 stock options.
• He also indirectly beneficially owns 341,574 shares through Partners Innovation Fund, LLC (PIF I) and 232,727 shares through Partners Innovation Fund II, L.P. (PIF II), where he is a partner and may share voting and investment power.

Sentiment

Score: 7

Explanation: The filing indicates a director receiving equity compensation, which is generally a positive sign of continued commitment and alignment of interests with shareholders. It's a routine transaction, not indicative of major positive or negative news, hence a neutral-to-positive score.

Positives

• Director Julius Knowles received equity compensation (RSUs and stock options), which aligns his financial interests with those of the company's shareholders.
• The RSUs were granted at a price of $0, representing direct equity ownership upon vesting.
• The grant of stock options provides an incentive for long-term performance and value creation.
• The continued service requirement for vesting indicates ongoing commitment from the director.

Negatives

• No specific negative aspects are disclosed in this routine compensation filing.

Risks

• The value of the equity compensation (RSUs and stock options) is subject to the future performance and market price fluctuations of Keros Therapeutics, Inc. common stock.
• Vesting of the equity awards is contingent upon the Reporting Person's continued service to the Issuer.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend into 2026, indicating a continued commitment from Director Julius Knowles to Keros Therapeutics, Inc. and aligning his future incentives with the company's performance.

Industry Context

This filing represents a standard practice in the biotechnology and pharmaceutical industry where directors and key personnel receive equity compensation to align their long-term interests with the company's success and shareholder value creation. Such grants are common for retaining talent and incentivizing performance in growth-oriented sectors.

Comparison to Industry Standards

• The grant of RSUs and stock options to a director is a common compensation practice across the biotech and broader public company landscape, comparable to compensation structures seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, though specific grant sizes vary based on company size, stage, and individual contribution.
• The vesting schedules (e.g., 12 months for options, up to 2026 for RSUs) are typical for director equity awards, designed to ensure continued service and long-term alignment, similar to those observed in peer companies within the small to mid-cap biotechnology sector.
• The exercise price of $14.82 for options is likely based on the market price at the time of grant, a standard practice to ensure options have intrinsic value only if the stock price appreciates.

Corporate Governance

Related Party Transactions

• Julius Knowles, as a Director and partner in Partners Innovation Fund, LLC (PIF I) and Partners Innovation Fund II, L.P. (PIF II), has indirect beneficial ownership of 341,574 and 232,727 shares of Common Stock, respectively, through these entities. This represents a related party holding arrangement.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder interests, potentially leading to better long-term performance and governance.
• Employees: While not directly impacting employees, a stable and incentivized board can contribute to overall company stability and strategic direction.

Next Steps

• Continued service of Julius Knowles to Keros Therapeutics, Inc.
• Vesting of the 5,250 restricted stock units on or before June 4, 2026.
• Quarterly vesting of the 10,500 stock options over the next 12 months, fully vested by the 2026 annual meeting.

Key Dates

Recommendation

Keywords

Keros Therapeutics, KROS, SEC Form 4, Beneficial Ownership, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Director Compensation, Insider Trading, Julius Knowles